Li Liu

Dr. Li Liu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2013 in World Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
JFJun-Fen Fu
Jun-Fen Fu
LLLi Liang
Li Liang
CGChun-Xiu Gong
Chun-Xiu Gong
FXFeng Xiong
Feng Xiong
FLFei-Hong Luo
Fei-Hong Luo
HWHai-Yan Wei
Hai-Yan Wei

15 May 2015 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
LTLieqi Tang
Lieqi Tang
MPMinzhi Peng
Minzhi Peng
LLLi Liu
Li Liu
WCWenhan Chang
Wenhan Chang
HBHenry J. Binder
Henry J. Binder
SCSam X. Cheng
Sam X. Cheng
Colonic bicarbonate (HCO3−) secretion is a well-established physiological process that is closely linked to overall fluid and electrolyte movement in the mammalian colon. These present studies show that extracellular calcium-sensing receptor (CaSR), a fundamental mechanism for sensing and regulating ionic and nutrient compositions of extracellular milieu in the small and large intestine, regulates HCO3− secretion. Basal and induced HCO3− secretory responses to CaSR agonists were determined by pH stat techniques used in conjunction with short-circuit current measurements in mucosa from rat distal colon mounted in Ussing chambers. R568, a specific CaSR activator, stimulated lumen Cl−- and short-chain fatty acid (SCFA)-dependent HCO3− secretion but inhibited cyclic nucleotide-activated HCO3− secretion. Consequently, at physiological conditions (either at basal or during lumen acid challenge) when electroneutral Cl−/HCO3− and SCFA/HCO3− exchangers dominate, CaSR stimulates HCO3− secretion; in contrast, in experimental conditions that stimulate fluid and HCO3− secretion, e.g., when forskolin activates electrogenic cystic fibrosis transmembrane conductance regulator-mediated HCO3− conductance, CaSR activation inhibits HCO3− secretion. Corresponding changes in JHCO3 (μeq·h−1·cm−2, absence vs. presence of R568) were 0.18 ± 0.03 vs. 0.31 ± 0.08 under basal nonstimulated conditions and 1.85 ± 0.23 vs. 0.45 ± 0.06 under forskolin-stimulated conditions. Similarly, activation of CaSR by R568 stimulated Cl−- and SCFA-dependent HCO3− secretion and inhibited cAMP-dependent HCO3− secretion in colon mucosa of wild-type mice; such effects were abolished in CaSR-null mice. These results suggest a new paradigm for regulation of intestinal ion transport in which HCO3− secretion may be fine-tuned by CaSR in accordance with nutrient availability and state of digestion and absorption. The ability of CaSR agonists to inhibit secretagogue-induced intestinal HCO3− secretion suggests that modulation of CaSR activity may provide a new therapeutic approach to correct HCO3− deficit and metabolic acidosis, a primary cause of morbidity and mortality in acute infectious diarrheal illnesses.

1 December 2013 in Journal of Chromatography A
Verified
Journal Article
Closed access
MPMinzhi Peng
Minzhi Peng
XFXiefan Fang
Xiefan Fang
YHYonglan Huang
Yonglan Huang
YCYanna Cai
Yanna Cai
CLCuili Liang
Cuili Liang
LLLi Liu
Li Liu

1 August 2013 in Journal of Chromatography B
Verified
Journal Article
Closed access
MPMinzhi Peng
Minzhi Peng
LLLi Liu
Li Liu
MJMinyan Jiang
Minyan Jiang
CLCuili Liang
Cuili Liang
XZXiaoyuan Zhao
Xiaoyuan Zhao
HLHong Luo
Hong Luo

1 January 2017 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
XCXiaodan Chen
Xiaodan Chen
LLLi Liu
Li Liu
Background: Congenital cataract is one of the major causes of blindness and amblyopia in children. About one-third of the cases are inherited.Case presentation: We applied whole exome sequencing for a pediatric patient with congenital cataract, small penis, baldness and absence of eyebrows and detected a compound heterozygous mutation in the lanosterol synthase (Conclusions: We concluded that the mutations affect the structural stability of the protein to some extent.

21 January 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LHLing Hou
Ling Hou
KHKe Huang
Ke Huang
CGChunxiu Gong
Chunxiu Gong
FLFeihong Luo
Feihong Luo
WHwei haiyan
wei haiyan
Xiaoping LuoXiaoping Luo
Xiaoping Luo
Context The evidence of long-term polyethylene glycol recombinant human GH (PEG-rhGH) in pediatric GH deficiency (GHD) is limited. Objective This study aimed to examine the effectiveness and safety of long-term PEG-rhGH in children with GHD in the real world, as well as to examine the effects of dose on patient outcomes. Design A prospective, observational, posttrial study (NCT03290235). Setting, participants and intervention Children with GHD were enrolled from 81 centers in China in 4 individual clinical trials and received weekly 0.2 mg/kg/wk (high-dose) or 0.1 to <0.2 mg/kg/wk (low-dose) PEG-rhGH for 30 months. Main outcomes measures Height SD score (Ht SDS) at 12, 24, and 36 months. Results A total of 1170 children were enrolled in this posttrial study, with 642 patients in the high-dose subgroup and 528 in the low-dose subgroup. The Ht SDS improved significantly after treatment in the total population (P < 0.0001), with a mean change of 0.53 ± 0.30, 0.89 ± 0.48, 1.35 ± 0.63, 1.63 ± 0.75 at 6 months, 12 months, 24 months, and 36 months, respectively. In addition, the changes in Ht SDS from baseline were significantly improved in the high-dose subgroup compared with the low-dose subgroup at 6, 12, 24, and 36 months after treatment (all P < 0.05). A total of 12 (1.03%) patients developed serious adverse events. There was no serious adverse event related to the treatment, and no AEs leading to treatment discontinuation or death occurred. Conclusions PEG-rhGH showed long-term effectiveness and safety in treating children with GHD. Both dose subgroups showed promising outcomes, whereas PEG-rhGH 0.2 mg/kg/wk might show additional benefit.